05-06-2020
Pavel Kapysh / Shutterstock.com
The advocate general has recommended that the Court of Justice of the European Union (CJEU) uphold an almost €94 million ($106.5 million) fine imposed on Lundbeck for its pay-for-delay scheme.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
CJEU, advocate general, Lundbeck, generics, pay-for-delay, competition law, patent settlement, citalopram
Fifth circuit denies Impax pay-for-delay petition
15-04-2021
Lundbeck loses €150m pay-for-delay appeal
30-03-2021
EC fines Teva €60.5m over pay-for-delay deal
27-11-2020
US states sue 26 drugmakers over alleged price fixing
11-06-2020
Par avoids pay-for-delay suit after court accepts payment was ‘fair’
10-03-2020
CJEU issues clarification on UK’s pay-for-delay generics ruling
31-01-2020
